Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AMB-131
- Development stage
- Preclinical
- Lead developer
- Ambrosia Biosciences
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
AMB-131 is an investigational, oral small-molecule GIP (gastric inhibitory polypeptide) receptor antagonist being developed by Ambrosia Biosciences. It is designed to block the GIP receptor, offering a novel mechanism for the treatment of obesity and other metabolic disorders. The drug's nonclinical profile was presented at ObesityWeek 2026, highlighting its potential as a next-generation oral therapy that can be used as a standalone treatment or in strategic combinations for cardiometabolic diseases.
02
Targets
Beyond the preview
Go deeper on AMB-131.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AMB-131.
Work on AMB-131? Claim this page to correct or add information. Claim this page